In Brief: Extended-Release Budesonide (Ortikos) for Crohn ' s Disease

Date: November 2, 2020
Issue #: 
1610Summary: 
An oral extended-release formulation of the corticosteroid
budesonide (Ortikos– Ferring) is now available
for once-daily treatment of mild to moderate active
Crohn ' s disease of the ileum and/or ascending colon in
patients ≥8 years old and for maintenance of remission
for up to 3 months in adults.Ortikos is the second oral
formulation of budesonide to be approved for this
indication;Entocort EC, an ileal-release formulation,
was the first. A third oral formulation of budesonide(Uceris) is approved for induction of remission in
patients with mild to moderate active ulcerative colitis.

Source: The Medical Letter - October 13, 2020 Category: Drugs & Pharmacology Authors: admin Source Type: research